SCHEMBL27228498

SCHEMBL27228498

Cc1ccc2nn(C)cc2c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ NSD2 O96028 1/20 0.42
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ LMNA P02545 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ ADORA1 P30542 3/20 0.36
▸ ADORA2A P29274 2/20 0.36
▸ ADORA3 P0DMS8 1/20 0.35
▸ POLB P06746 2/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ NOS3 P29474 1/20 0.32
▸ NOS2 P35228 1/20 0.32
▸ USP7 Q93009 1/20 0.32
▸ BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23207357 0.81 MAPT (0.42) MAPTKDM4EALDH1A1NSD2MEN1
SCHEMBL19538835 0.80 PDE3B (0.40) MAPTKDM4EALDH1A1NSD2ADORA1
SCHEMBL31500716 0.79 KDM4E (0.41) MAPTKDM4EALDH1A1NSD2ADORA1
SCHEMBL27228241 0.79 KDM4E (0.41) MAPTKDM4EALDH1A1NSD2ADORA1
SCHEMBL27191847 0.77 MAPT (0.34) MAPTKDM4EALDH1A1NSD2ADORA1
SCHEMBL23508730 0.77 PTPN11 (0.37) MAPTKDM4EALDH1A1NSD2ADORA1
SCHEMBL24163247 0.77 MAPT (0.37) MAPTKDM4EALDH1A1NSD2LMNA
SCHEMBL27227930 0.77 KDM4E (0.42) MAPTKDM4EALDH1A1NSD2MEN1
SCHEMBL27031852 0.77 DPP4 (0.35) MAPTKDM4EALDH1A1NSD2ADORA1
Hydrochloric Acid SCHEMBL21986792 0.75 DPP4 (0.35) MAPTKDM4EALDH1A1NSD2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-05-30 — — US disclosed
WO-2024073073-A2 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF LRRK2, MAP3K20, MAP3K5 MAPT 623/4885KDM4E 1085/4885ALDH1A1 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback